Hepatocellular carcinoma surveillance—Utilization, barriers and the impact of changing aetiology

DQ Huang, AG Singal, F Kanwal… - Nature Reviews …, 2023 - nature.com
Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide.
Surveillance for HCC is critical for early detection and treatment, but fewer than one-quarter …

Blood-based biomarkers for hepatocellular carcinoma screening: Approaching the end of the ultrasound era?

ND Parikh, N Tayob, AG Singal - Journal of hepatology, 2023 - Elsevier
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide, in
part because of inadequate early detection strategies. Current recommendations for …

Battle of the biopsies: Role of tissue and liquid biopsy in hepatocellular carcinoma

BM Lehrich, J Zhang, SP Monga, R Dhanasekaran - Journal of hepatology, 2024 - Elsevier
The diagnosis and management of hepatocellular carcinoma (HCC) have improved
significantly in recent years. With the introduction of immunotherapy-based combination …

Guidelines for the prevention and treatment of chronic hepatitis B (version 2022)

H You, FS Wang, T Li, X Xu, Y Sun, Y Nan… - Infectious Diseases & …, 2023 - mednexus.org
To facilitate the achieving of the goal of" eliminating viral hepatitis as a major public health
threat by 2030" set by the World Health Organization, the Chinese Society of Hepatology …

Risk stratification and early detection biomarkers for precision HCC screening

YT Lee, N Fujiwara, JD Yang, Y Hoshida - Hepatology, 2023 - journals.lww.com
Hepatocellular carcinoma (HCC) mortality remains high primarily due to late diagnosis as a
consequence of failed early detection. Professional societies recommend semi‐annual HCC …

Biomarker discovery in hepatocellular carcinoma (HCC) for personalized treatment and enhanced prognosis

B Yu, W Ma - Cytokine & Growth Factor Reviews, 2024 - Elsevier
Hepatocellular carcinoma (HCC) is a leading contributor to cancer-related deaths worldwide
and presents significant challenges in diagnosis and treatment due to its heterogeneous …

Updating the clinical application of blood biomarkers and their algorithms in the diagnosis and surveillance of hepatocellular carcinoma: a critical review

E Shahini, G Pasculli, AG Solimando, C Tiribelli… - International Journal of …, 2023 - mdpi.com
The most common primary liver cancer is hepatocellular carcinoma (HCC), and its mortality
rate is increasing globally. The overall 5-year survival of patients with liver cancer is …

[HTML][HTML] Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region

BN Toan, CK Tan, I Hasan, L Setiawan… - Clinical and …, 2023 - ncbi.nlm.nih.gov
Even though the combined use of ultrasound (US) and alpha-fetoprotein (AFP) is
recommended for the surveillance of hepatocellular carcinoma (HCC), the utilization of AFP …

The performance of GALAD score for diagnosing hepatocellular carcinoma in patients with chronic liver diseases: a systematic review and meta-analysis

MC Guan, SY Zhang, Q Ding, N Li, TT Fu… - Journal of Clinical …, 2023 - mdpi.com
Background GALAD score, comprising five clinical parameters, is a predictive model
developed for hepatocellular carcinoma (HCC) detection. Since its emergence, its …

HES V2. 0 outperforms GALAD for detection of HCC: A phase 3 biomarker study in the United States

HB El-Serag, Q **, N Tayob, E Salem, M Luster… - Hepatology, 2025 - journals.lww.com
Hepatology AASLD Publications Hepatology Liver Transplantation Hepatology Communications
Clinical Liver Disease Log in or Register Subscribe to journalSubscribe Get new issue …